Chromium and vanadate combination increases insulin-induced glucose uptake by 3T3-L1 adipocytes

Biochemical and Biophysical Research Communications

Volumn 347, Issue 3, 2006, Pages 769-773

  Brautigan, David L ^a   Kruszewski, Allison ^a   Wang, Hong ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

4E BP1; GLUT4; MAPK; P Tyr; PTP

Indexed keywords

BIOLOGICAL MARKER; CHROMIUM; CHROMIUM HISTIDINE; GLUCOSE; INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TYROSINE; UNCLASSIFIED DRUG; VANADIC ACID;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; GLUCOSE TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CHROMIUM; GLUCOSE; INSULIN; MICE; PHOSPHOTYROSINE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; VANADATES;

EID: 33746190648     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.154     Document Type: Article

References (29)

1. Committee on Animal Nutrition Board on Agriculture National Research Council, The Role of Chromium in Animal Nutrition, National Academy Press, Washington, DC, 1997.
2. Mertz W., and Schwarz K. Relation of glucose tolerance factor to impaired intravenous glucose tolerance of rats on stock diets. Am. J. Physiol. 196 (1959) 614-618
3. Jeejeebhoy K.N., Chu R.C., Marliss E.B., Greenberg G.R., and Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am. J. Clin. Nutr. 30 (1977) 531-538
4. Mertz W. Chromium in human nutrition: a review. J. Nutr. 123 (1993) 626-633
5. Anderson R.A. Chromium as an essential nutrient for humans. Regul. Toxicol. Pharmacol. 26 (1997) S35-S41
6. Schwarz K., and Mertz W. Chromium(III) and the glucose tolerance factor. Arch. Biochem. Biophys. 85 (1959) 292-295
7. Mertz W. Effects and metabolism of glucose tolerance factor. Nutr. Rev. 33 (1975) 129-135
8. Yamamoto A., Wada O., and Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur. J. Biochem. 165 (1987) 627-631
9. Yamamoto A., Wada O., and Suzuki H. Purification and properties of biologically active chromium complex from bovine colostrum. J. Nutr. 118 (1988) 39-45
10. Toepfer E.W., Mertz W., Polansky M.M., Roginski E.E., and Wolf W.R. Preparation of chromium-containing material of glucose tolerance factor activity from brewer's yeast extracts and by synthesis. J. Agric. Food Chem. 25 (1976) 162-166
11. Vincent J.B. Recent developments in the biochemistry of chromium(III). Biol. Trace Elem. Res. 99 (2004) 1-16
12. Shechter Y. Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39 (1990) 1-5
13. Orvig C., Thompson K.H., Battell M., and McNeill J.H. Vanadium compounds as insulin mimics. Met. Ions Biol. Syst. 31 (1995) 575-594
14. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., and Kahn C.R. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol. Cell. Biochem. 153 (1995) 217-231
15. Bevan A.P., Drake P.G., Yale J.F., Shaver A., and Posner B.I. Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Mol. Cell. Biochem. 153 (1995) 49-58
16. McNeill J.H., Yuen V.G., Dai S., and Orvig C. Increased potency of vanadium using organic ligands. Mol. Cell. Biochem. 153 (1995) 175-180
17. Goldwaser I., Gefel D., Gershonov E., Fridkin M., and Shechter Y. Insulin-like effects of vanadium: basic and clinical implications. J. Inorg. Biochem. 80 (2000) 21-25
18. Swarup G., Cohen S., and Garbers D.L. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem. Biophys. Res. Commun. 107 (1982) 1104-1109
19. Fantus I.G., Deragon G., Lai R., and Tang S. Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Mol. Cell. Biochem. 153 (1995) 103-112
20. Anderson R.A. Chromium in the prevention and control of diabetes. Diabetes Metab. 26 (2000) 22-27
21. Morris B.W., Kouta S., Robinson R., MacNeil S., and Heller S. Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabet. Med. 17 (2000) 684-685
22. Sakurai H. A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chem. Rec. 2 (2002) 237-248
23. Guerrero-Romero F., and Rodriguez-Moran M. Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants. Arch. Med. Res. 36 (2005) 250-257
24. Green H., and Meuth M. An established pre-adipose cell line and its differentiation in culture. Cell 3 (1974) 127-133
25. Wang H., Kruszewski A., and Brautigan D.L. Cellular chromium enhances activation of insulin receptor kinase. Biochemistry 44 (2005) 8167-8175
26. Beretta L., Gingras A.C., Svitkin Y.V., Hall M.N., and Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 15 (1996) 658-664
27. Chen G., Liu P., Pattar G.R., Tackett L., Bhonagiri P., Strawbridge A.B., and Elmendorf J.S. Chromium activates GLUT4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol. Endocrinol. (2005)
28. Yang X., Palanichamy K., Ontko A.C., Rao M.N., Fang C.X., Ren J., and Sreejayan N. A newly synthetic chromium complex-chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett. 579 (2005) 1458-1464
29. Wang Z.Q., Zhang X.H., Russell J.C., Hulver M., and Cefalu W.T. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J. Nutr. 136 (2006) 415-420